New results from the North American COVID-19 STEMI (NACMI) registry showed a 25% reduction in early mortality in 2021 compared to 2020 among STEMI patients with a confirmed COVID-19 infection.
The new recommendations went live just ahead of ACC.22. They can be read in full in the Journal of the American College of Cardiology, Circulation or Journal of Cardiac Failure.
One researcher described the findings, presented at the Heart Failure Society of America's Annual Scientific Meeting, as "great news for patients and clinicians."
Patients presenting with an acute myocardial infarction during the start of the COVID-19 pandemic faced delays in care and a higher risk of developing heart failure.
Expertise and commitment of FDA reviewers remain in place, but the agency’s ability to communicate openly with industry has become a significant concern.
The law reflects growing interest in using existing imaging studies to identify cardiovascular disease risk without requiring additional scans, radiation exposure or costs.